Pharmacokinetics/Pharmacodynamics of Albiglutide
Completed
The first part of the study includes a single dose treatment period to evaluate the pharmacokinetic bioequivalence of a subcutaneous injection of albiglutide from process 2 drug substance compared with process 3 drug substance. The second part of the treatment period will evaluate additional pharmacokinetic and pharmacodynamic parameters and safety and tolerability of repeat doses of albiglutide given weekly for 12 weeks from process 2 drug substance compared with process 3 drug substance. Subje... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
11/18/2016
Locations: GSK Investigational Site, Houston, Texas +5 locations
Conditions: Diabetes Mellitus, Type 2
Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes
Completed
The purpose of this study is to determine if albiglutide is safe and effective in the treatment of type 2 diabetes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/18/2016
Locations: GSK Investigational Site, Arlington, Texas +40 locations
Conditions: Diabetes Mellitus, Type 2
Out-Patient Study in Patients With Type 2 Diabetes Mellitus Who Are Taking no Diabetes Medication or Metformin Only
Completed
This study is a placebo-controlled study in patients with Type 2 Diabetes Mellitus who are either taking no diabetes medication or who are taking metformin only. This study will investigate the safety, tolerability, and efficacy of Albiglutide (GSK716155) and will measure the levels of Albiglutide (GSK716155) in the bloodstream when it is given for 16 weeks. As a comparison, some subjects will receive exenatide instead of Albiglutide (GSK716155). The study will involve weekly visits for 17 weeks... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
11/03/2016
Locations: GSK Investigational Site, Cleburne, Texas +22 locations
Conditions: Diabetes Mellitus, Type 2
The Effect of VTC-G15 (a Pentapeptide Cleavage Product og GLP-1) on Whole Body Glucose Metabolism in Man
Unknown
To asses the modulating properties of the cleaved pentapeptide product of GLP-1 amide.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/07/2015
Locations: ICON PLC, San Antonio, Texas
Conditions: Insulin Resistance